Allopurinol showed no clear difference in acute gout attacks compared with placebo (moderate certainty).
Allopurinol showed no clear difference in acute gout attacks compared with benzbromarone (low certainty).
Allopurinol showed no clear difference in proportion achieving target serum urate compared with benzbromarone (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Allopurinol probably leads to higher proportion achieving target serum urate compared with placebo (moderate certainty).
Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Allopurinol 100‐300 mg daily showed no clear difference in withdrawal due to adverse effects compared with febuxostat 80 mg daily (moderate certainty).